These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27089618)

  • 1. [Novel insulins].
    Eriksson JG; Laine MK
    Duodecim; 2016; 132(5):447-51. PubMed ID: 27089618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating advances in insulin into clinical practice: Overview of current insulin formulations.
    Rhinehart AS
    J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S4-8. PubMed ID: 24080572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin degludec: a new insulin for today?
    Hitman GA
    Diabet Med; 2013 Nov; 30(11):1267. PubMed ID: 24134602
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
    Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
    Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin: Making Sense of Current Options.
    Segal AR; Vootla T; Beaser RS
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):845-874. PubMed ID: 27823608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
    Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher concentration insulins: an overview of clinical considerations.
    Reid TS; Schafer F; Brusko C
    Postgrad Med; 2017 Jun; 129(5):554-562. PubMed ID: 28475455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
    Muñoz Torres M
    Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Glargine U-300 (Toujeo®): A Review.
    Grant JS; Graven LJ
    Home Healthc Now; 2016 Mar; 34(3):156-7. PubMed ID: 26925942
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy.
    Cammarota S; Bruzzese D; Catapano AL; Citarella A; De Luca L; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Putignano D; Tragni E; Novellino E; Riccardi G
    Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):10-7. PubMed ID: 23806740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing glycemic control with insulin glargine.
    Williams JB
    Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
    [No Abstract]   [Full Text] [Related]  

  • 20. Will the next generation of basal insulins offer clinical advantages?
    Garber AJ
    Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.